Eur J Vasc Endovasc Surg 2022 May 19. Epub 2022 May 19.
German Aortic Center, Department of Vascular Medicine, University Heart Center Hamburg, Hamburg, Germany. Electronic address:
Objectives: Females are at higher mortality risk after endovascular aortic repair. This study aimed to compare the 30-day and 12-month mortality, morbidity and re-intervention rates between sexes, treated with fenestrated or branched endovascular aortic repair (F/BEVAR).
Design: This meta-analysis was conducted according to PRISMA statement, and its protocol was registered to PROSPERO (CRD42021273418). A search of the English literature, via Ovid, using MEDLINE, EMBASE, and CENTRAL databases, until 30 July 2021, was performed.
Materials: Observational studies (2010-2021), with ≥20 patients, reporting on sex specific outcomes; mortality, acute kidney injury (AKI), spinal cord ischemia (SCI), and re-intervention, after F/BEVAR, were considered eligible.
Methods: Studies' bias was assessed using ROBINS-I and evidence quality using GRADE. The primary outcome was the sex specific 30-day mortality, AKI, SCI, and reintervention and secondary, survival and freedom from re-intervention at 12-months after F/BEVAR. The outcomes were summarized as odds ratio (OR) with 95% confidence intervals (CI).
Results: Four retrospective and one prospective study (2,421 patients; 26% females) were included. 30-day mortality was 12% in females, vs. 3% in males (OR, 2.65; 95% CI, 1.79, 3.92; Ι=0%). 30-day AKI, SCI and re-intervention rates were similar (OR, 1.45; 95% CI, 1.03, 2.03, Ι=0%; OR 1.86; 95% CI, 1.27, 2.74; Ι=38%; OR, 1.06; 95% CI, 0.66, 1.77; Ι=0%). 12-month survival rate was lower in females (OR, 0.95; 95% CI, 0.91, 0.99; Ι=38%). When excluding 30-day mortality, the 12-month survival showed no difference between sexes (OR, 0.99; 95% CI 0.95-1.02; Ι=32%). The 12-month freedom from re-intervention was similar between sexes (OR, 0.87; 95% CI, 0.75, 1.01; Ι=0%).
Conclusion: Female patients treated with F/BEVAR may present worse outcomes in terms of 30-day and 12-month survival. The high peri-operative mortality is still an issue. When excluding 30-day mortality, the 12-month survival is similar between sexes. Early morbidity and re-intervention rates seem comparable.